 |
Peter spent over twelve years with Kidder, Peabody and DLJ, most recently as a vice president in the corporate services division. During that time he assisted in originating investment banking transactions in the public and private markets with companies such as Qwest Communications International, Somatogen, IVAC Medical Systems (now Alaris), Spectranetics, IMSI, Triad and others.
Since 1989, he has been, individually and through SVP I and II, an early stage investor in numerous successful seed and early stage companies, including CV Therapeutics (CVTX), Chili!Soft, Speedchain Networks, ARYx Therapeutics, Lifeline Technologies, Overread, Hall-Kinion (HAKI), Cambric, Z-force (now Attune Systems) and others. Peter has also served on numerous boards including Aryx Therapeutics, Speedchain Networks, IntelliDOT Corporation, Navitas Cancer Rehabilitation Centers and as a board observer for a number of other companies including Health Hero Networks and CV Therapeutics. He is focused on opportunities in the health care and IT sectors.
Peter's private equity invetments, prior to the formation of Shoreline include -
Cobalt, purchased by Sun Microsystems (NASDAQ: SUNW) in 2000, is an integral part of a powerful new software architecture that allows third-party developers to drop their applications directly into the Sun Cobalt Qube appliance making it the perfect platform for the delivery of their products. The Sun Cobalt Qube 3 appliance is a complete system, requires no additional add-ons and enables the user to leverage the power of the Internet on his/her own terms.
Cambric Corporation is the premier provider of Digital Engineering Services to leading automotive, aerospace and manufacturing companies. Cambric’s Data Transition and Collaborative Engineering services support the rapid transition to new digital engineering systems and improve overall levels of innovation, quality and cost-effectiveness. Founded in 1989, Cambric develops and refines the best methods for creating intelligent data for digital engineering systems, including 3D solid modeling, CAD, and GIS.
CV Therapeutics, Inc. (NASDAQ:CVTX), headquartered in Palo Alto, California, is a biopharmaceutical company focused on the discovery, development, and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.
As a pioneer in the field of molecular cardiology, CV Therapeutics strives to discover new solutions for the unmet medical needs of patients. The company employs more than 500 professionals, including a cardiovascular sales force of approximately 200 field-based individuals. Nearly 19 percent of employees based in our Palo Alto headquarters hold doctoral degrees, including MDs, PhDs, and PharmDs.
|
